Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Explore mechanism data, evidence tiers, safety, and regulatory context for every compound in the Fnx catalog. Each peptide has its own research profile, filter by category or follow a tag from any product page.
FDA approved with randomized controlled trials behind the approved use.
A large or maturing human RCT base, but not (yet) FDA approved for this use.
Registered and used abroad (e.g. Russia) on modest, mostly single institution trials.
A plausible mechanism, but human efficacy for the marketed use is unproven.
Animal/in vitro data and anecdote only, little to no human evidence and real safety unknowns.
A GHRH analog paired with a selective ghrelin receptor agonist, combined to synergistically stimulate pulsatile growth hormone release.
The GHRH(1-29) fragment, the shortest fully active GHRH sequence, used to stimulate physiologic, pulsatile growth hormone secretion.
An orally active non peptide ghrelin receptor agonist that reliably raises GH and IGF-1, studied across GH deficiency, sarcopenia, and aging, with a notable cardiac safety flag.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) analog of the pineal peptide epithalamin, studied for telomerase activation and pineal/melatonin rhythm regulation in aging models.
A short chain tripeptide bioregulator (Glu-Asp-Arg) from the Khavinson program, studied for neuroprotection and a proposed, but under validated, direct gene promoter binding mechanism.